MetaVia (MTVA) Competitors $0.65 -0.01 (-2.10%) As of 07/3/2025 01:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesSEC FilingsTrendsBuy This Stock MTVA vs. IFRX, TELO, CNTX, AVTX, SNTI, CNTB, STTK, ADVM, ATNM, and RNXTShould you be buying MetaVia stock or one of its competitors? The main competitors of MetaVia include InflaRx (IFRX), Telomir Pharmaceuticals (TELO), Context Therapeutics (CNTX), Avalo Therapeutics (AVTX), Senti Biosciences (SNTI), Connect Biopharma (CNTB), Shattuck Labs (STTK), Adverum Biotechnologies (ADVM), Actinium Pharmaceuticals (ATNM), and RenovoRx (RNXT). These companies are all part of the "pharmaceutical products" industry. MetaVia vs. Its Competitors InflaRx Telomir Pharmaceuticals Context Therapeutics Avalo Therapeutics Senti Biosciences Connect Biopharma Shattuck Labs Adverum Biotechnologies Actinium Pharmaceuticals RenovoRx MetaVia (NASDAQ:MTVA) and InflaRx (NASDAQ:IFRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability. Which has more volatility & risk, MTVA or IFRX? MetaVia has a beta of 0.21, indicating that its share price is 79% less volatile than the S&P 500. Comparatively, InflaRx has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500. Do insiders and institutionals hold more shares of MTVA or IFRX? 1.4% of MetaVia shares are held by institutional investors. Comparatively, 42.4% of InflaRx shares are held by institutional investors. 0.8% of MetaVia shares are held by insiders. Comparatively, 16.3% of InflaRx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media favor MTVA or IFRX? In the previous week, InflaRx had 1 more articles in the media than MetaVia. MarketBeat recorded 2 mentions for InflaRx and 1 mentions for MetaVia. MetaVia's average media sentiment score of 0.00 equaled InflaRx'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MetaVia 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral InflaRx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is MTVA or IFRX more profitable? InflaRx's return on equity of -64.17% beat MetaVia's return on equity.Company Net Margins Return on Equity Return on Assets MetaViaN/A -222.13% -123.85% InflaRx N/A -64.17%-53.39% Which has stronger earnings and valuation, MTVA or IFRX? MetaVia has higher earnings, but lower revenue than InflaRx. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMetaViaN/AN/A-$27.59MN/AN/AInflaRx$180K300.22-$49.85M-$0.82-0.98 Do analysts recommend MTVA or IFRX? MetaVia currently has a consensus price target of $7.50, suggesting a potential upside of 1,057.59%. InflaRx has a consensus price target of $6.60, suggesting a potential upside of 719.88%. Given MetaVia's higher probable upside, equities research analysts plainly believe MetaVia is more favorable than InflaRx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MetaVia 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00InflaRx 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryInflaRx beats MetaVia on 8 of the 10 factors compared between the two stocks. Get MetaVia News Delivered to You Automatically Sign up to receive the latest news and ratings for MTVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MTVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTVA vs. The Competition Export to ExcelMetricMetaViaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.96M$2.91B$5.53B$8.95BDividend YieldN/A2.42%5.38%4.09%P/E RatioN/A21.5627.4020.24Price / SalesN/A277.33417.66125.07Price / CashN/A41.9536.6357.47Price / Book0.707.518.085.67Net Income-$27.59M-$55.05M$3.16B$248.47M7 Day Performance2.84%4.59%2.81%3.29%1 Month Performance-5.68%4.86%3.69%5.18%1 Year PerformanceN/A5.82%35.30%21.35% MetaVia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTVAMetaVia1.5483 of 5 stars$0.65-2.1%$7.50+1,057.6%N/A$12.96MN/A0.008Gap DownIFRXInflaRx2.7213 of 5 stars$0.80-0.5%$6.60+729.1%-50.6%$53.23M$180K-0.9760News CoverageTELOTelomir Pharmaceuticals2.8366 of 5 stars$1.78+1.1%$15.00+742.7%-68.5%$52.97MN/A-4.241CNTXContext Therapeutics3.3678 of 5 stars$0.59+1.8%$6.00+923.9%-63.4%$52.57MN/A-1.897AVTXAvalo Therapeutics3.0694 of 5 stars$4.85-2.1%$30.00+519.2%-57.0%$52.46M$441K0.0040News CoverageSNTISenti Biosciences2.7455 of 5 stars$2.01+0.3%$8.50+323.9%-30.3%$52.29M$2.56M-0.184CNTBConnect Biopharma3.3516 of 5 stars$0.94-1.5%$7.00+643.9%-12.7%$52.28M$26.03M0.00110News CoveragePositive NewsSTTKShattuck Labs2.8881 of 5 stars$1.10+5.8%$7.50+584.9%-77.4%$51.97M$5.72M-0.78100Gap UpADVMAdverum Biotechnologies4.2542 of 5 stars$2.48-2.4%$26.75+978.6%-66.5%$51.81M$1M-0.39190ATNMActinium Pharmaceuticals2.5124 of 5 stars$1.66-2.1%$4.00+140.4%N/A$51.63M$81K-1.1930RNXTRenovoRx2.9119 of 5 stars$1.37-3.5%$7.25+429.2%+20.5%$50.10M$240K-3.436Positive News Related Companies and Tools Related Companies IFRX Alternatives TELO Alternatives CNTX Alternatives AVTX Alternatives SNTI Alternatives CNTB Alternatives STTK Alternatives ADVM Alternatives ATNM Alternatives RNXT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MTVA) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MetaVia Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MetaVia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
